Improving Boron Neutron Capture Therapy for Liver Tumors
Author Information
Author(s): Fujii Hitoshi, Matsuyama Akifumi, Komoda Hiroshi, Sasai Masao, Suzuki Minoru, Asano Tomoyuki, Doki Yuichiro, Kirihata Mitsunori, Ono Koji, Tabata Yasuhiko, Kaneda Yasufumi, Sawa Yoshiki, Lee Chun Man
Primary Institution: Osaka University Graduate School of Medicine
Hypothesis
Can cationized gelatin-HVJ envelope with sodium borocaptate enhance the efficacy of BNCT for liver tumors?
Conclusion
The study found that CG-HVJ-E-BSH significantly improved the effectiveness of BNCT for treating liver tumors without harming surrounding normal tissues.
Supporting Evidence
- CG-HVJ-E reduced hemagglutination activity by half compared to HVJ-E.
- Higher 10B concentrations were achieved in tumor cells with CG-HVJ-E-BSH than with BSH.
- CG-HVJ-E-BSH significantly increased the survival time of tumor-bearing mice compared to BSH.
Takeaway
Researchers created a new delivery method for a cancer treatment that helps target liver tumors better while keeping healthy tissue safe.
Methodology
The study involved developing a new vector for boron delivery and testing its effectiveness in a murine model of liver tumors.
Limitations
The study was conducted in a murine model, which may not fully replicate human responses.
Participant Demographics
Female C3H/HeN Jcl mice, 8-12 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website